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Abstract
Background The use of smoking cessation medications
can considerably enhance the long-term abstinence rate at a
reasonable cost, but only a small proportion of quitters seek
medical assistance. The objective of this study was to
evaluate the factors that influence the decision to use such
treatments and the willingness-to-pay of smokers for
improved cessation drugs.
Method A discrete choice experiment was conducted
amongst smokers in the French-speaking part of Switzer-
land. Choice sets consisted of two hypothetical medications
described via five attributes (price, efficacy, possibility of
minor side effects, attenuation of weight gain and avail-
ability) and an opt-out option. Various discrete choice
models were estimated to analyse both the factors that
influence treatment choice and those that influence the
overall propensity to use a smoking cessation medication.
Results Our results indicate that smokers are willing to
pay for higher efficacy, less-frequent side effects and pre-
vention of weight gain. Whether the drug is available over-
the-counter or on medical prescription is of secondary
importance. In addition, we show that there are several
individual-specific factors influencing the decision to use
such medications, including education level. Results also
indicate substantial preference heterogeneity.
Conclusion This study shows that there is a potential
demand for improved cessation medications. Broader
usage could be reached through lower out-of-pocket price
and greater efficacy. Secondary aspects such as side effects
and weight gain should also be taken into consideration.
Keywords Discrete choice experiments 
Smoking cessation  Preference heterogeneity
JEL Classification I11  I12  D12  C25
Introduction
Smoking is the leading preventable cause of death in most
developed countries. Switzerland is no exception, with
more than nine thousand deaths attributable to tobacco use
each year [1]. The proportion of daily or occasional
smokers in the population between 14 and 65 years old was
approximately 27% in 2009 [2], which is quite high in
comparison with other developed countries. This high
prevalence rate is partly due to permissive tobacco legis-
lation. This was confirmed in a study by Joossens and Raw
[3] grading the tobacco control intensity at the country
level, in which Switzerland was ranked 18th amongst 30
European countries, mainly due to lack of restrictions and
low prices. Switzerland is also home to several interna-
tional tobacco companies that have substantial influence in
political decisions.
A lower prevalence of smoking could be achieved by
increasing the success rate of individuals who try to quit.
Indeed, many smokers are motivated to quit and do make
the attempt,1 but only a few succeed over the long term.
One reason is that few seek assistance, even though the
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long-term abstinence rate can be considerably enhanced
with appropriate cessation support. The estimated cold
turkey (i.e., smoking cessation without assistance) quit rate
is approximately 5%, whilst a 10–20% long-term quit rate
can be achieved with the most effective interventions [4].
Amongst the wide range of smoking cessation interven-
tions, we distinguish non-pharmaceutical (medical coun-
selling, group therapies, books, help line, acupuncture, etc.)
from pharmaceutical (nicotine replacement therapies2—or
NRTs—and nicotine-free medications)3 treatments. The
latter were found to be effective versus placebo in several
randomised controlled trials [5].
This study focuses on nicotine-free smoking cessation
medications, and its main objective is to assess smokers’
preferences for such products. Our goal was threefold: to
highlight the most important factors that influence the
decision to use such treatment, to assess the value that
smokers attach to attribute improvements, and to analyse
preference heterogeneity. We used a discrete choice
experiment (DCE)—a stated preferences (SP) technique—
which consisted of presenting a sample of respondents with
choices between several hypothetical treatments. The
medications were described via five attributes (price, effi-
cacy, side effects, effect on weight gain, and availability).
The respondents were asked to choose several times
between two alternative treatments and an opt-out option.
We analysed choice data starting from the simple multi-
nomial logit model (MNL) as the benchmark model. We
then estimated more complex models that were able to take
into account the specifics of the choice process and the
panel structure of the data (i.e., each respondent makes
several choices). Using the nested logit (NL) framework,
we analysed both the influence of the product’s charac-
teristics on choice and the impact of individual character-
istics on the propensity to use such medications. Then,
random parameter logit (RPL) models allowed us to take
unobserved heterogeneity into account.
The results consistently show that smokers value med-
ications that have improved efficacy and less-frequent side
effects and that prevent weight gain after cessation. In
addition, we show that there are several individual factors
that influence the decision to use such medications. We
also show the importance to account for unobserved
heterogeneity when analysing choice data. This informa-
tion should help guide the efforts of smoking cessation
actors (pharmaceutical industry, public health decision
makers) to improve treatment acceptance and usage and
thereby achieve higher cessation rates in the population.
Related work
Researchers have extensively applied DCE in the fields of
marketing, transport and environmental economics. In
health economics, the number of DCE studies has sharply
increased during the past decade [8–12]. More specifically,
many DCE applications have aimed to evaluate the health
and non-health dimensions of medical treatments, for
example: miscarriage management [13]; varicella vacci-
nation [14]; insulin mixtures [15]; alcoholism medication
[16]; colorectal cancer screening [17]; weight loss pro-
grammes [18]; knee injuries detection [19]; and lower
urinary tract symptoms [20]. In Table 1, we provide a non-
exhaustive list of empirical papers using DCE to value
medical interventions along with the dimensions that were
assessed.
Pharmaceutical smoking cessation treatments have
been analysed from an economic point of view, espe-
cially with respect to cost-effectiveness [21–24], and all
studies have concluded that these treatments lead to a
low cost per life-year saved. In a cost-effectiveness study
conducted in six western countries, Cornuz et al. [22]
found a cost per life-year saved of US $792 for a
45-year-old smoker using Zyban (bupropion) in Swit-
zerland. Researchers have also examined the demand for
smoking cessation therapies by focusing on various
determinants. Tauras and Chaloupka [25] found that
decreasing the price of NRTs would lead to an increase
in sales of these products (estimated average price
elasticity of -2.33 for patches and of -2.46 for gums).
The effects of conversion to over-the-counter (OTC)
status for nicotine patches and gums were analysed by
Keeler et al. [26]. The authors estimated that after the
conversion, the use of both therapies would increase
substantially (78–92% for patches and 180% for nicotine
gum). Halpin et al. [27] investigated the demand of the
general population for health insurance coverage exten-
sion to cover treatment for tobacco dependence, and they
found that most people were willing to accept an
increase of at least US $3 in their basic health insurance
premium to finance the coverage. Avery et al. [28]
analysed the impact of smoking cessation product
advertising on the purchasing of such products and on
smoking behaviour. They found that the probabilities of
attempting to quit and of quitting were positively asso-
ciated with higher exposure to such advertising.
2 NRTs partially relieve the withdrawal symptoms that people
experience when they quit, by compensating for the lack of nicotine
in the organism. There are several NRTs currently available over-the-
counter in Switzerland, including patches, gum, inhalers, lozenges
and nasal sprays.
3 Two nicotine-free medications are available in Switzerland by
medical prescription only (A list): bupropion (brand name Zyban),
whose exact mode of action is still unclear [6], and varenicline (brand
name Champix), which relieves symptoms of nicotine withdrawal
and blocks the reinforcing effect of continued nicotine use through an
antagonist and agonist action [7].
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Two studies used stated preferences methods to inves-
tigate individual preferences for smoking cessation treat-
ments. Busch et al. [29] applied contingent valuation (CV)
to estimate willingness-to-pay (WTP) for medications that
are more effective and that attenuate weight gain associated
with smoking cessation. About 80% of the respondents
were willing to pay for greater effectiveness, and two-
thirds of these individuals were willing to pay more if the
treatment had an impact on weight gain. These authors also
estimated that the mean WTP for a 100% effective treat-
ment—i.e. the value of a statistical quit—was US $538.
The major limitation of CV is that it does not allow many
dimensions of the good to be estimated at a time. The good
has a value per se, and it is not possible to assess the
relative importance of its dimensions. Paterson et al. [30]
overcame this limitation by applying labelled4 DCE to the
choice of smoking cessation therapies (nicotine gum,
nicotine patch, nicotine inhaler and Zyban). They used
cost, success rate and treatment length as variable attributes,
with doses per day and availability as fixed characteristics.
The flexibility of the model specifications they applied
allowed the authors to investigate preference heterogeneity.
They found that effectiveness was a primary consideration.
Light and heavy smokers were both willing to pay sub-
stantial amounts for improved success rates (i.e., CAN
$500 and CAN $300 to achieve a 40% success rate).
We chose to use unlabelled choice experiments to focus
on treatments’ characteristics without connecting them to
existing therapies. In addition to price and efficacy, we
focus on minor side effects, attenuation of weight gain and
availability. We study preference heterogeneity by
including individuals’ characteristics in our modelling
framework (1) as a part of the choice process and (2)
directly through interactions with medication attributes.
We also investigate unobserved heterogeneity by allowing
tastes to vary across respondents using RPL models.
Framework for analysis
A majority of current smokers positively value the benefits
associated with smoking cessation, resulting in a desire to
quit and in frequent quit attempts. Most of these attempts
are made cold turkey and thus have a relatively low long-
term success rate. Relapses are frequent, particularly
because of the significant costs associated with nicotine
withdrawal. The use of a smoking cessation drug partially
relieves the craving symptoms, resulting in increased
success rates. The demand for such a product depends on
the perceived additional net benefits it provides over
alternative methods. For simplification purpose, we assume
here that the only available alternative method is cold
turkey cessation. Thus, in our analysis, we interpret opting
out as the decision to use cold turkey cessation instead of a
medication. The additional benefit of the treatment is the
value the individual attaches to smoking cessation multi-
plied by the increased probability of successfully quitting
that the treatment provides.5 The probability of long-term
Table 1 Published studies using DCE to value medical interventions
Authors Treatment Dimension valued
Ryan et al. [13] Miscarriage management Pain, time in hospital, time to return to normal activities, cost, complications
Hall et al. [14] Varicella vaccination Risk of mild side effects, risk of severe side effects, vaccine effectiveness, health
authority support, location for vaccination, price of vaccination
Aristides et al. [15] Insulin mixtures Timing of injection before meal, 2-h postprandial blood glucose, effect of prandial
dosing, nocturnal hypoglycaemic frequency
Mark et al. [16] Alcoholism medication % of treated population who remained abstinent, % of patients who had no incidence of
heavy drinking, % of patients that experienced mild side effects, % of patients who
complied at a high rate, mode of action, route of administration, price per day
Marshall et al. [17] Colorectal cancer screening Process, preparation, pain, specificity, sensitivity
Roux et al. [18] Weight loss programmes Programme cost, travel time to programme, amount of doctor involvement, programme
components emphasised, focus of programme
Bryan et al. [19] Knee injury detection % chance of requiring arthroscopy, time from initial consultation to end of treatment, %
chance that knee problem is completely resolved, total cost to the patient
Watson et al. [20] Lower urinary tract symptoms Time to symptom improvement, treatment decreases prostate size, sexual side effects of
treatment, nonsexual side effects of treatment, treatment cost, % chance of surgery
4 Also known as alternative-specific choice experiments. DCEs that
use generic titles for the alternatives are called unlabelled DCEs,
contrary to labelled choice experiments, where each alternative refers
to a particular commodity (e.g., Zyban) [31].
5 The perceived value of quitting is defined as ‘‘the difference
between the lifetime utility from quitting and the lifetime utility from
continuing to smoke’’ (Avery et al. [28]).
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abstinence is negatively related to withdrawal symptoms.
The medication precisely increases the success rate by
decreasing these withdrawal symptoms. The benefits also
include additional features of the medication, such as its
ability to reduce weight gain associated with smoking
cessation.
The benefits of the treatment are compared to its costs,
which include both the out-of-pocket cost, and other
non-monetary costs such as side effects, and time and effort
to purchase the treatment, which is related to treatment
availability. A smoker will decide to use a smoking
cessation treatment when making a quit attempt if the
perceived net benefits are positive. We expect potential
quitters to positively value efficacy and the additional
benefits of the medication, and to negatively value side
effects and access costs.
Materials and method
The DCE method is based on the hypothesis that any good or
service can be described as a set of characteristics or attri-
butes. Consistent with Lancaster’s theory of value [32],
individuals do not appreciate commodities globally, but
rather as a sum of attributes. In contrast to revealed prefer-
ence techniques that analyse choices observed in reality,
DCEs—as a stated preference technique—consist of pre-
senting hypothetical choice situations (‘choice sets’, here-
after) to a sample of respondents. Each choice set contains
two or more alternatives that vary according to the level of
their attributes. It is assumed that individuals select the
alternative from which they derive the highest utility. The
probability of an alternative being chosen is then modelled in
accordance with the random utility framework [33].
Applying appropriate econometric techniques to analyse
observed decisions, the researcher is able to retrieve the
indirect utility functions of individuals in the attribute-space.
The researcher is then able to estimate the relative
importance of the attributes (marginal rates of substitution).
When a monetary attribute is included, it is possible to esti-
mate marginal willingness-to-pay (mWTP) for improve-
ments in attributes and, by extension, global WTP for
improved medications. Individual-specific characteristics
that might influence the choice can also be included in the
models. As mentioned by Ryan et al. [34], a complete DCE
study is a complex process that involves three main steps
prior to the econometric treatment: (1) definition of attributes
and attribute levels; (2) experimental design and construc-
tion of choice sets and (3) data collection.
Definition of attributes and attribute levels
From existing literature, we initially developed a list of
attributes about smoking cessation pharmaceutical treat-
ments [5, 35, 36] that seemed the most relevant to our
research goals: price, efficacy, length of the treatment,
possibility of minor side effects, attenuation of weight gain
and availability. Meanwhile, we conducted two focus
groups with five participants in order to identify important
attributes and prevent the omission of salient ones. The
length of the treatment was found to be of low importance
and was therefore excluded.
The next step consisted of assigning levels to each
attribute. The literature recommends that these should be
realistic, well-defined, plausible and should potentially
involve trade-offs [34]. The first three attributes describe
continuous dimensions, whereas the latter two are dichot-
omous. Levels for price were defined on the basis of true
market prices. For instance, the out-of-pocket cost of a
comprehensive treatment course with Zyban (bupropion)
is about CHF 300 [6]. A central advantage of DCE is that it
allows larger attribute variability. The price attribute was
therefore described with four possible levels within a
plausible interval (CHF 200–CHF 500).
We can express long-term efficacy in an absolute or
relative way. Many studies report the efficacy of a medi-
cation relative to a placebo or relative to an alternative
treatment in terms of odds ratios [5], whilst evaluations of
absolute long-term abstinence rate are also possible [4].
Because it is difficult for respondents to interpret odds
ratios, we chose to use the following definition of efficacy:
the proportion of quitters who still do not smoke 1 year
after treatment. The quit rate at 1 year is approximately 5%
for smokers without assistance [4], 15% for those with
bupropion and 22% for those with varenicline (Gonzales
et al. [7]; Jorenby et al. [37]). Selected levels for the
Table 2 Attributes and levels
Attributes Levels Opt out
Price: price for the complete treatment (PRICE) CHF 200, CHF 300, CHF 400, CHF 500 CHF 0
Efficacy: abstinence rate at 1 year (EFF) 15, 25, 40, 50% 5%
Side effects: risk of benign side effects (SIDEF) 10, 30, 50% 0%
Attenuation of weight gain associated with smoking cessation
(WEIGHT)
Yes, no No
Availability (AVAIL) Over-the-counter (not restricted), medical prescription Not restricted
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medications were 15% (close to bupropion), 25% (close to
varenicline), 40% and 50% (improved efficacy). The most
commonly reported benign side effects of bupropion and
varenicline are insomnia, nausea and dry mouth [4, 7, 38],
and these are quite frequent (30% for bupropion and 50%
for varenicline). In addition to these two side-effect levels,
we chose a third (10%) to depict an improved medication.
Weight gain is strongly associated with smoking cessation,
with the average gain after cessation reaching approxi-
mately 4–5 kg (Froom et al. [39], Klesges et al. [40];
Williamson et al. [41]). Some smokers are discouraged
from cessation because of this tendency. An improved
medication could include components that prevent weight
gain (Meyers et al. [42]). Finally, medications are either
available over-the-counter or are obtainable only with a
medical prescription. All the attributes and their respective
levels are presented in Table 2. The table also shows the
levels assumed for the opt-out option (baseline levels).
Experimental design
Choice sets presented to respondents contained two unla-
belled alternatives (‘medication A’ and ‘medication B’).
Because our target population had not necessarily decided
to use such a medication at the time of the study, we also
included an opt-out option to allow individuals to be non-
demanders [43]. With two four-level attributes, one three-
level attribute and two dichotomous attributes, the full
factorial design gives rise to 192 (42 9 3 9 22) possible
hypothetical medications. We used a fractional factorial
design in order to reduce the possible combinations. Choice
sets were generated starting from a resolution 3 orthogonal
array obtained on Sloane’s website [44] and using the
method proposed by Street and Burgess [45]. We obtained
an orthogonal main effects plan (OMEP), whose efficiency
compared with an optimal design is 96.04% [46]. The
design produced 16 distinct choice sets that were divided
into 2 blocks of 8 choice sets [31]. Each respondent was
then assigned randomly to any of the two blocks.
To verify the consistency of responses, it is customary to
add constructed scenarios to the main design. Thus, we
created two additional choice sets containing a dominant
alternative. Dominance is achieved when one alternative is
superior for at least one attribute whilst the other attributes
are at the same level.6 Respondents are supposed to choose
the dominant (or the opt out) alternative if rationality holds.
In summary, we presented ten choice sets to each respon-
dent, two of which were consistency checks [47, 48].
Questionnaire and data collection
The questionnaire was first pre-tested in a sample of 25
respondents to collect comments, suggestions and personal
evaluations of the task difficulty, giving rise to the final
version of the questionnaire. Then, two hundred and thirty
subjects were recruited from the French-speaking part of
Switzerland. The main inclusion criteria were age between
15 and 64 years and being a daily or occasional smoker. The
respondents also had to express an interest in quitting
smoking. The sample was representative of the French-
speaking Swiss population of smokers with respect to age,
gender and education level. The questionnaire was divided
into two parts: the choice experiments and the collection of
individual information. In the DCE part, respondents were
asked to imagine the following scenario (in brief):
‘‘You have decided to quit smoking, and you have the
possibility to be supported by a smoking cessation
medication that can improve your chance of quitting
(without any help, the success rate at 1 year is 5%)…
You will be presented with 10 situations in which two
medications are described. Please choose, for each
situation, if you would buy medication A, medication
B or neither’’.
We then gave a detailed description of each attribute and
presented their respective levels. The same information was
also provided in the presentation of each choice set, an
example of which is shown in ‘Appendix’. In the second part
of the questionnaire, we gathered information about smoking
history, quitting history, health status and demographics.
Econometric analysis
Discrete choice modelling relies on the random utility
theory [33], where the utility that individuals derive from
an alternative is divided into two components: a systematic
(observable) and a stochastic (unobservable) one. It is
assumed that the former depends linearly on attribute levels
whilst the latter is due to unobserved information and
measurement errors. More formally, we denote the utility
that individual i derives from alternative j by:
Uij ¼ Vij þ eij; ð1Þ
Where Vij is the observable component and eij the random
error. With k attributes, assuming a linear utility function,
we have the following functional form:
Vij ¼ b1Xij1 þ b2Xij2 þ    þ bkXijk ¼ X0ijb: ð2Þ
Under the assumption of rationality, individuals choose the
alternative from which the utility derived is the highest.
Therefore, alternative j will be chosen over alternative q if
6 For instance, if we compare two medications, one that has a lower
price, higher efficacy and fewer side-effects, with the other attributes
being at the same level, is considered dominant.
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Uij [ Uiq: ð3Þ
From this, we derive the probability that individual i
chooses alternative j amongst p alternatives:
Pij ¼ ProbðVij þ eij [ Vip þ eip8p 6¼ jÞ: ð4Þ
Identically,
Pij ¼ ProbðVij  Vip [ eip  eij8p 6¼ jÞ: ð5Þ
The resulting choice model depends on the assumption
made about the distribution and the correlation structure of
the error term. Below, we describe three choice models that
differ in their complexity: the multinomial logit model
(MNL), the nested logit model (NL) and the random
parameter logit model (RPL).
Multinomial logit
If we assume that the errors are independent and identically
distributed (IID) Type I Extreme Value, we obtain the
standard multinomial logit (MNL) specification. After
some algebraic manipulations (see McFadden [49] or Train
[50] for details), we obtain the following expression for the
choice probabilities:
Pij ¼
exp X0ijb
 
P
p exp X
0
ipb
  ð6Þ
The IID assumption induces the independence from
irrelevant alternatives (IIA) axiom, which means that the
relative probability of choosing one alternative over
another is unaffected by the presence of additional
alternatives in the choice set [51]. In other words, the
IIA property implies that all alternatives are perfect
substitutes. In this case, the choice sets included three
alternatives (medication A, medication B and the opt-out
option). If IIA holds, this would mean that, for example,
an improvement in medication A would lead to
proportionate decreases in the frequencies at which
medication B and opting out are chosen. Here, it is
likely that an improvement in medication A would
produce a larger decrease in the probability of choosing
medication B than of choosing the opt-out option.
Another limitation of the simple MNL specification is
that it does not take into account the fact that each
respondent faces several choice situations and that there
might be correlation across choice sets faced by a single
individual. To handle these limitations, we estimated two
additional models allowing for more complex
substitution patterns and for possible correlation across
choice situations.
Nested logit
In this specification, similar alternatives are partitioned into
subsets called nests. For any two alternatives (say, a and b)
in the same nest, ea is correlated with eb, whereas for any
two alternatives in different nests, the unobserved portion
of utility is uncorrelated.7 In our case, the first nest holds
the medications (A and B), whilst the second nest contains
only the opt-out option. For clarity, we can visualise each
choice as the result of two decisions. First, individuals
decide whether or not to opt out. Then, conditional on not
having chosen the opt-out option, they choose a medication
according to the attribute levels. A suitable way to illustrate
the model structure is with a tree diagram (Fig. 1). The
‘branches’ denote the alternative subsets within which IIA
holds, and the ‘leaves’ are the alternatives.
The probability that individual i chooses alternative j
within nest n (which contains Jn alternatives) can be
depicted as the product of two probabilities [33]: the
probability of choosing nest n amongst N nests and the
conditional probability of alternative j being chosen (given
that nest n is chosen):
Pijn ¼ Pnestn  Pjjnestn ð7Þ
with
Pnest n ¼ e
z
0
ncþsnIVn
PN
n¼1 ez
0
ncþsnIVn
ð8Þ
and
Pjjnestn ¼ e
x
0
jjnb
PJn
j¼1 e
x
0
jjnb
; ð9Þ
where z is a vector of individual-specific characteristics,
x is a vector of medication attributes, c and b are vectors of
parameters, and IV is the so-called inclusive value with its
Fig. 1 Nested logit structure
7 IIA holds in the same nest but not across different nests.
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associated inclusive value parameter s [50]. The inclu-
sive value (IV) parameter is an indicator of the degree of
substitutability between the alternatives. When it equals
one, all alternatives are perfectly substitutable. In this
case, the model collapses to the simple multinomial logit
model (MNL), and there is no need to use a more
flexible specification. If the IV parameter equals zero,
this means that the choice amongst nests is completely
independent of the choice amongst the alternatives. In
such a case, one independent choice model per decision
can be estimated. The use of the NL specification is
appropriate when the IV parameter lies between zero and
one because this means that alternatives within a nest are
closer substitutes for each other than for alternatives in
other nests [50].
Random parameter logit
The random parameter logit model (RPL), also referred
as mixed logit, allows for more flexible substitution
patterns and takes into account the influence of unob-
served individual characteristics on choices. In this
framework, the choice probability is a weighted average
of the multinomial logit choice probabilities, where the
weights are the possible values of b. The researcher must
then specify a distribution for the coefficients with
parameters h, i.e., f ðb hj Þ:
Pij ¼
Z exp X0ijb
 
P
p exp X
0
ipb
 
0
@
1
Af ðb hj Þdb ð10Þ
Most commonly, it is assumed that the b’s are normally
distributed. The log-normal distribution is also often used,
in particular for the coefficients that are assumed to be
strictly positive. We can interpret the RPL model as a
model in which the parameters are randomly distributed
across individuals. The utility of the j-th alternative for an
individual i can be written as:
Uij ¼ X0ijbi þ eij ð11Þ
where the bi’s are the random coefficients that we can
decompose into two parts, as follows:
bi ¼ b þ gi ð12Þ
where b is the population mean and gi is a stochastic
deviation representing preference heterogeneity. Re-
writing the model, we obtain:
Uij ¼ X0ijb þ X0ijgi þ eij ð13Þ
The stochastic portion of utility (i.e., X0ijgi þ eij) is corre-
lated across choice situations due to the common influence
of gi. Since the integral in (10) has no closed-form, simu-
lation is used to estimate the parameters.8
Model specification
In all the models, the choice amongst alternatives depends
on the five attributes: price (Price), efficacy (Eff), side
effects (Side), effect on weight gain (Weight) and avail-
ability (Avail), all as defined above in Table 2. The utility
function is simply:
Uij ¼ b1Priceij þ b2Effij þ b3Sideij þ b4Weightij
þ b5Availij þ eij: ð14Þ
In addition, in the NL model, the opt-out decision is assumed
to depend on a series of individual-specific characteristics
and on the attributes [see (8)]. Individual-specific variables
include the number of years the respondent has smoked
(Years_sm), the previous use of any smoking cessation help
(Help), gender (Gender), whether the respondent is anxious
(Anx), educational level (Sec and Sup), and the presence of
any children in the household (Child).
In the RPL model, the parameters were assumed to be
normally distributed in the basic specification:
Uij ¼ b1iPriceij þ b2iEffij þ b3iSideij þ b4iWeightij
þ b5iAvailij þ eij ð15Þ
with bki Nðbk; rkÞ. We also estimated models in which
coefficients of Price and Eff where assumed to be log-
normally distributed (price was then entered negatively in
the specification).
To go further into the investigation of preference heter-
ogeneity, we estimated models that include interaction terms
between individual-specific characteristics and some
attributes, as suggested by Ryan et al. [52]. We created an
interaction between price and indicators corresponding to
three levels of monthly income, i.e. Price 9 Inc1,
Price 9 Inc2, and Price 9 Inc3, where Inci is an indicator for
the i-th of the following income groups:\CHF 4,500, CHF
4,500–8,500 and [8,500 CHF. We created an additional
interaction term between body mass index and the attribute
Weight, using two subgroups (Bmi1: up to 25 kg/m
2 and
Bmi2: over 25 kg/m
2). The general form of the utility func-
tion including interaction terms was:
Uij ¼d1Priceij þ d2ðPrice  Inc2Þij þ d3ðPrice  Inc3Þij
þ d4Effij þ d5Sideij þ d6Weightij
þ d7ðWeight  Bmi2Þij þ d8Availij þ eij ð16Þ
Because individuals with higher income are supposed to
8 In short, draws from f ðb hj Þ are used to get a simulated value of the
log-likelihood function. This is done for different values of h, until we
obtain the maximum simulated likelihood (Train [50]).
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have a lower marginal valuation of money, we expect d2
and d3 to be positive (leading to a smaller negative impact
of price on utility in these income groups). We also assume
that individuals with BMI over 25 attach a higher value to
the weight attribute, i.e., that d7 is positive.
Results
Descriptive statistics
Between March and April 2008, 230 paper-and-pencil
questionnaires were mailed. A response rate of 60% was
achieved (138 surveys collected). We excluded five
respondents due to missing data, making the total number
of valid questionnaires 133 (69 from the first block and 64
from the second block). Only two individuals failed the
dominance test, i.e., chose the non-dominant alternative.
We excluded them from the sample, resulting in 131
individuals who were used for the model estimations
(yielding 1,048 observations). Amongst the 1,048
(131 9 8) choice responses, the opt-out option was selec-
ted 491 times (46.9%). In the sample, 24 individuals
always chose the opt-out option (no treatment). This sub-
group is defined as serial non-participants [53]. Some
authors suggest dropping these individuals from the sample
to carry out the estimations, because some of these indi-
viduals are likely to opt out as a way of protesting. Deleting
these responses can lead to inconsistent estimates, and the
nested logit structure used here allows us to explain the
factors that influence non-participation; therefore, we did
not drop these respondents.
Table 3 summarises statistics about smoking and quit-
ting history, health status and socio-economic characteris-
tics. The mean age of the sample is 38.8 years; the
distribution amongst the different age groups is close to the
distribution in the French-speaking Swiss population of
smokers. Respondents with higher education levels were
slightly overrepresented, to the detriment of the population
with only secondary education. Only five respondents had a
Fagerstro¨m Test for Nicotine Dependence (FTND) score
over seven. On average, the respondents had smoked for
20 years, and two-thirds of them had already tried to quit at
least once for at least 2 weeks. Amongst these unsuccessful
quitters, the mean number of quit attempts was 2.63
(std.dev. 2.52), and 23% of the individuals had already
used a pharmaceutical smoking cessation therapy, mostly
NRT. A large majority of the respondents (67%) were
confident about their ability to quit, although only 24%
were actually planning to quit within the next 6 months.
Table 3 Descriptive statistics (N = 131)
Variable Definition Mean Std. dev.
Smoking history
Years_sm Number of years smoking 19.9 11.88
Lowdep =1 if FTND score \4 0.67
Middep =1 if FTND is between 4 and 7 0.29
Highdep =1 if FTND [7 0.04
Smoking cessation
Help =1 if have ever used NRT or Zyban 0.23 2.50
Attempts Number of previous quit attempts 2.72
Ability =1 if confident about ability to quit 0.67
Quit 6 months =1 if plans to quit within the next 6 months 0.24
Health state
Health =1 if feels in excellent health 0.22 3.29
Bmi Respondent’s body mass index 23.9
Anx =1 if very anxious 0.08
Household characteristics
Hhinc Household monthly income (CHF) 6,393.1 3,021
Child =1 if there are any children 0.35
Respondent’s characteristics
Gender =1 if resp. is a male 0.56 12.13
Age Age in years 38.7
Prim =1 if primary education 0.21
Sec =1 if secondary education 0.57
Sup =1 if higher education 0.22
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The results from the MNL and NL models are presented
in Table 4, results from the RPL models are in Table 5, and
results of the models that include interactions are presented
in Table 6. All estimations were performed using Stata
version 10.0 (Stata Corp., Texas, USA). In all models, the
coefficients of the utility function are highly significant and
of the expected sign except for availability, which is sig-
nificant only in one of the RPL models (Model 5). First,
focusing on the results of the simple MNL model (Model
1), we observe that higher price and a higher prevalence of
side effects both give rise to lower utility whilst long-term
efficacy is positively valued. An interesting result is the
considerable importance that potential quitters attach to the
presence of an effect on weight gain. However, the relative
importance of this characteristic might be biased upwards
because the attribute is presented as a dichotomous (yes/
no) option whilst price, efficacy and side effects are pre-
sented in percentage.9 The two additional MNL models
include an alternative-specific constant (ASC) for the opt-
out option, as a fixed effect in Model 2, and as a random
effect in Model 3. The ASC is significant and positive in
both cases, indicating a propensity to choose the opt-out
option, even after accounting for differences in attributes.
This suggests the presence of an opt-out bias amongst
respondents that might reflect the fact that respondents opt
out because decisions are hard to make. We investigated
this issue in comparing opt-out rates across choice sets, and
we do not find evidence of higher opt-out rates in choice
sets with more similar alternatives. Another possible
interpretation is that the benefits of the presented alterna-
tives rarely outweigh the observed and unobserved costs of
using a medication.
In the first column of Table 4, we provide the results of
the Hausman–McFadden test [54], which tests the IIA
assumption. The procedure consists of re-estimating the
model based on a subset of alternatives. If IIA holds,
the parameters in both models should be the same. The
Hausman–McFadden statistic tests the equality of the
parameters, and its associated statistic is assumed to follow
a Chi-square distribution. The high value of the Chi-square
statistic indicates that the assumption of IIA (and thus, the
MNL model) is not sustainable in this choice context
(P \ 0.05). This result supports the use of a more flexible
specification. Looking at the NL specification (Model 4),
we notice that the IV parameter associated with the treat-
ment branch is significant and lies between zero and one,10
indicating that the separation of alternatives into nests is
appropriate. Then, we focus on the second part of the NL
model (opt-out decision). Because we modelled the prob-
ability of opting out, a negative significant coefficient
associated with a variable means that an increase of that
variable decreases the probability of opting out (or, simi-
larly, increases the probability of choosing a medication).
This is the case for the variable child (P \ 0.05); indi-
viduals who have children are less likely to opt out. An
explanation would be that those individuals are more
motivated to quit because they include their children’s
future health status in their decision process. The coeffi-
cient for higher education is also significant and negative
(P \ 0.01), the reference category being primary educa-
tion. This could denote better perception and understanding
of the potential benefits of smoking cessation amongst
more educated individuals. By contrast, two variables have
a positive and significant coefficient. Smokers who have
smoked for a greater number of years are more likely to opt
out (P \ 0.05). This result is difficult to explain because
these individuals are more strongly addicted and thus
should benefit more from a medication that relieves with-
drawal symptoms. Possible explanations could be that
long-term smokers are simply reluctant to use drugs to
handle their smoking habit, that they are overconfident
about their future ability to quit, or that their perceived
benefits of cessation are low. Anxiety has a positive impact
on opting out (P \ 0.01). This could reflect lower per-
ceived benefits of cessation amongst anxious individuals
because of a stronger psychological addiction.
The estimation results of the RPL models are presented
in Table 5. In Models 5 and 6, all coefficients are assumed
to be normally distributed whilst in Models 7 and 8, the
coefficients for Price and Eff are assumed to follow a
log-normal distribution. Unlike in previous models, the
coefficient associated with availability is positive and sig-
nificant (P \ 0.05), but only in Model 5. This result pro-
vides some evidence that individuals would positively
value a switch to ‘OTC status’ for these drugs. Because we
have random coefficients, we also provide estimates of the
associated standard deviations. Their significance (except
for Avail) indicates the presence of preference heteroge-
neity. Taking this heterogeneity and possible correlation
across choices into account seems to bring significant
improvements in terms of goodness-of-fit. Model 6 is the
preferred specification regarding the log-likelihood, and
both the AIC and BIC criteria. Models that include inter-
actions between the price attribute and income and between
the weight attribute and BMI are presented in Table 6. The
results consistently show that the relative importance of the
price attribute is lower for individuals with higher income.
Moreover, we see that overweight individuals (BMI [ 25)
value the fact that a treatment prevents weight gain more
highly, but not significantly.
9 In order to assess potential non-linearity within these attributes, a
MNL model was also estimated using the levels of the attributes in the
utility function (the levels were effects coded [31]). Results, available
upon request, show that the linearity assumption is reasonable.
10 The IV parameter associated with the opt-out option was set to
one.
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Table 4 Estimation results—MNL and NL models
Utility function MNL MNL MNL NL
Model 1 Model 2 Model 3 Model 4
Opt-out ASC (fixed) – 0.6289**
(0.2637)
– –
Opt-out ASC(random) – – 0.6675*
(0.4018)
[2.78***]
–
Price -0.0044***
(0.0004)
-0.0036***
(0.0005)
-
0.0051***
(0.0007)
-
0.0033***
(0.0005)
Eff 0.0543***
(0.0038)
0.0590***
(0.0044)
0.0821***
(0.0062)
0.0434***
(0.0057)
Side -0.0358***
(0.0032)
-0.0320***
(0.0036)
-
0.0377***
(0.0042)
-
0.0266***
(0.0047)
Weight 0.7545***
(0.1055)
0.7653***
(0.1085)
0.9347***
(0.1235)
0.5610***
(0.1103)
Avail 0.0124
(0.0933)
0.0970
(0.1022)
0.0312
(0.1169)
0.0004
(0.0733)
Opt-out choice (NL only)
Years_sm 0.0126**
(0.0052)
Help -0.1243
(0.1456)
Gender -0.0316
(0.1292)
Anx 0.6767***
(0.2538)
Sec 0.0051
(0.1479)
Sup -
0.5852***
(0.1882)
Child -0.3159**
(0.1374)
IV parameter 0.6698***
(0.1136)
IIA test
Hausma–McFadden
Chi2
(P value)
6.40
(0.011)
N 1,048 1,048 1,048 1,048
AIC 1,904.4 1,900.6 1,520.5 1,884.8
BIC 1,934.8 1,937.0 1,563.0 1,975.9
ll -947.2 -944.3 -753.2 -927.4
In the MNL models, the opt-out option is defined with specific values for the attributes. In the NL model, the opt-out option has no associated
attribute value. Standard errors in parentheses. Standard deviation of random coefficients in brackets
* Significant at 10%
** Significant at 5%
*** Significant at 1%
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Welfare measures
The ratio between any two coefficients in (14), (15) or (16)
allows us to quantify the relative importance of the corre-
sponding attributes, i.e., the marginal rate of substitution
between them. If the price coefficient is included as the
denominator, we obtain a marginal willingness-to-pay
(mWTP) for the variation of an attribute. For example, we
can value the improvement of the efficacy of a treatment by
computing  b2=b1ð Þ ceteris paribus, i.e., the WTP for a
1-percentage-point increase in efficacy.
To compute mWTP estimates, we rely on the coeffi-
cients of the models without interactions (specifically, we
rely on estimates from Models 1, 3, 4 and 6). Dividing the
estimated coefficients of non-monetary attributes by the
negative of the price coefficient gives rise to mWTP esti-
mates. These are presented in Table 7. As suggested by
Hole, we applied the Krinsky-Robb method to compute
confidence intervals [55, 56].11 Table 8 presents the
mWTP estimated from the models with interactions.
Making some simple computations, one can derive from
the estimated WTP the incremental value of an improved
smoking cessation medication over cold-turkey cessation.
Using WTP estimates from the preferred specification
(Model 6) and assuming a linear relationship between WTP
and increased efficacy and between WTP and the preva-
lence of minor side effects, we compare cold turkey
cessation with a hypothetical medication that has the
Table 5 Estimation results—RPL models
Utility function Model 5 Model 6 Model 7 Model 8
Opt-out ASC – 0.4534
(0.4198)
[2.5180***]
– 0.5903
(0.4407)
[2.9714***]
Price -0.0095***
(0.0011)
[0.0078***]
-0.0074***
(0.0010)
[0.0040***]
-0.0093***
(0.0012)
[0.0111***]
-0.0082***
(0.0011)
[0.0069***]
Eff 0.1033***
(0.0092)
[0.0553***]
0.1086***
(0.0104)
[0.0665***]
0.1026***
(0.0091)
[0.0532***]
0.1113***
(0.0090)
[0.0516***]
Side -0.0694***
(0.0077)
[0.0562***]
-0.0662***
(0.0080)
[0.0511***]
-0.0583***
(0.0080)
[0.0515***]
-0.0564***
(0.0070)
[0.0352***]
Weight 1.3851***
(0.2274)
[1.9810***]
1.2978***
(0.2103)
[1.6125***]
1.1942***
(0.1980)
[1.2652***]
1.1317***
(0.1904)
[1.3486***]
Avail 0.3104**
(0.1416)
[0.1186]
0.2261
(0.1573)
[0.2147]
0.2050
(0.1298)
[0.0082]
0.1367
(0.1426)
[0.2086]
N 1,048 1,048 1,048 1,048
AIC 1,463.3 1,442.6 1,473.7 1,451.7
BIC 1,524.0 1,515.6 1,534.5 1,524.6
ll -721.6 -709.3 -726.9 -713.9
In the models, the opt-out option is defined with specific values for the attributes. In Models 5 and 6, all coefficients are normally distributed. In
Models 7 and 8, the coefficients for Price and Eff are log-normally distributed; all other coefficients are normally distributed. Thus, in Models 7
and 8, the parameters for Price and Eff are the means and std. dev. of the coefficients derived from the mean and std. dev. of the logarithm of the
coefficients (see e.g., Train [50] for the appropriate transformation). Standard errors in parentheses. Standard deviation of random coefficients in
brackets
* Significant at 10%
** Significant at 5%
*** Significant at 1%
11 This method, which is also referred to as parametric bootstrap,
consists of taking draws from a multivariate normal distribution with
means and covariance given by the estimated coefficients and the
associated variance–covariance matrix. Here, we performed 10,000
draws to obtain 10,000 values of the coefficients from the joint
distribution. We used these values to compute 10,000 mWTP
estimates for each non-price attribute. The 95% confidence interval
is then defined by taking the upper and lower 2.5 percentiles of the
distribution.
Assessing preferences for improved smoking cessation medications 543
123
following characteristics: 50% efficacy, 10% prevalence of
minor side effects, attenuation of weight gain and restricted
availability (45 9 14.6–10 9 8.9 ? 174.9 = 742.9). We
then multiply this amount by 0.54 (i.e., 1 minus the esti-
mated proportion of non-demanders). We obtain an incre-
mental value of the improved hypothetical smoking
cessation treatment over cold turkey of CHF 400. It is
worth noting that we make the conservative assumption
that the treatment has a value of zero for all non-
demanders, as in Busch et al. [29].
From the estimated RPL models, it is possible to obtain
individual-specific values for each coefficient conditional
on the choice actually made and the value of the attributes
[50, 57]. We exploit this information to plot distributions of
marginal WTP for each attribute (Fig. 2) in order to
illustrate the importance of preference heterogeneity.
Discussion
We used a discrete choice experiment to assess smokers’
preferences for hypothetical smoking cessation medications
described with five attributes: the price of a complete treat-
ment, the efficacy measured in terms of the probability of
becoming a successful long-term quitter, the occurrence of
minor side effects, whether the drug prevents weight gain
associated with smoking cessation and whether the product
is available over-the-counter. Such treatments primarily act
by reducing the withdrawal symptoms of smoking cessation,
therefore leading to increased success rates amongst users
compared to cold turkey quitters. However, currently
available products are costly, they are not yet reimbursed by
social health insurance, they cause frequent minor side
effects and they are not available over-the-counter.
Our results clearly show that there is potential demand
for improved smoking cessation medications. Even if a
considerable proportion of smokers who express interest in
Table 6 Estimation results—models with interactions
Utility function MNL NL RPL
Model 9 Model 10 Model 11
Opt-out ASC 0.6626*
(0.3942)
[2.6752***]
– 0.2729
(0.4130)
[2.2787***]
Price -0.0074***
(0.0012)
-0.0052***
(0.0007)
-0.0111***
(0.0015)
[0.0053***]
Price 9 Inc2 0.0027***
(0.0012)
0.0021***
(0.0005)
0.0034**
(0.0014)
[0.0020*]
Price 9 Inc3 0.0032***
(0.0015)
0.0033***
(0.0006)
0.0060***
(0.0016)
[0.0032]
Eff 0.0826***
(0.0062)
0.0470***
(0.0056)
0.1109***
(0.0097)
[0.0457***]
Side -0.0379***
(0.0042)
-0.0261***
(0.0046)
-0.0582***
(0.0066)
[0.0311***]
Weight 0.8116***
(0.1483)
0.5461***
(0.1253)
1.1101***
(0.2331)
[1.5877***]
Weight 9 Bmi2 0.3507
(0.2189)
0.1124
(0.1342)
0.0996
(0.4132)
[1.5815***]
Avail 0.0437
(0.1174)
0.0518
(0.0794)
0.2088
(0.3822)
[0.3822]
Opt-out choice (NL only)
Years_sm 0.0142***
(0.0053)
Help -0.1074
(0.1509)
Gender -0.0678
(0.1340)
Anx 0.4791*
(0.2640)
Sec 0.0999
(0.1544)
Sup -0.3342*
(0.1982)
Child -0.1041
(0.1443)
IV parameter 0.7171*** (0.1131)
N 1,048 1,048 1,048
AIC 1,517.5 1,850.8 1,450.9
BIC 1,578.2 1,948.1 1,560.3
Table 6 continued
Utility function MNL NL RPL
Model 9 Model 10 Model 11
ll -748.7 -909.4 -707.5
In the MNL and RPL models, the opt-out option is defined with
specific values for the attributes. In the NL model, the opt-out option
has no associated attribute value. The MNL model includes a random
opt-out ASC (normally distributed). All coefficients in Model 11 are
assumed to be normally distributed. Standard errors in parentheses.
Standard deviation of random coefficients in brackets
* Significant at 1%
** Significant at 5%
*** Significant at 10%
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quitting are not willing to purchase such medications (opt-
out rate of 46%), individuals are willing to pay significant
amounts for ameliorations of the relevant attributes. In line
with the findings of Busch et al. [29] and Paterson et al.
[30], we find that the probability of success is a funda-
mental characteristic. Individuals are willing to pay
Table 7 Marginal WTP estimates
Attribute Model 1 Model 3 Model 4 Model 6
Eff 12.3 (10.8;14.1) 16.2 (12.7;21.5) 13.0 (10.5;16.8) 14.6 (11.2;19.6)
Side -8.1 (-10.6;-6.2) -7.4 (-10.0;-5.4) -7.6 (-10.4;-5.5) -8.9 (-12.2;-6.4)
Weight 170.9 (125.1;221.8) 184.0 (133.8;252.9) 164.8 (115.4;224.8) 174.9 (121.4;246.4)
Avail 0 (–) 0 (–) 0 (–) 0 (–)
95% Krinsky-Robb confidence intervals in brackets
Table 8 Marginal WTP estimates by income group
Attribute Income groups (CHF)
\4,500 4,500–8,500 [8,500
Eff 8.6 (6.4;12.5) 14.8 (11.4;20.4) 22.6 (14.5;45.8)
Side -5.3 (-7.8;-3.7) -9.0 (-12.8;-6.4) -13.7 (-28.6;-8.4)
Weight (individuals with bmi \=25) 117.8 (76.4;182.0) 201.9 (132.9;296.7) 307.8 (182.7;610.4)
Weight (individuals with bmi [25) 123.4 (76.2;196.8) 211.5 (137.4;318.4) 322.4 (179.0;668.1)
95% Krinsky-Robb confidence intervals in brackets. Estimated coefficients and variance–covariance matrix from the RPL model with inter-
actions used (Model 11). WTP for Avail not reported (the associated coefficient is not significant)
Fig. 2 Preference heterogeneity—WTP distributions
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approximately CHF 12–16 for a 1% point increase in the
long-term success rate. This result indicates that the per-
ceived net benefits of quitting are important, at least for
demanders. Potential minor side effects, such as dry mouth
or nausea, for instance, dampen usage and are thus nega-
tively valued. A 1% point reduction in the probability of
experiencing minor side effects is valued at around CHF 8.
A striking figure is the substantial value (between CHF 160
and CHF 180, depending on the specification) that smokers
attach to the fact that the drug contains an active ingredient
that prevents cessation-related weight gain. This immediate
cost of smoking cessation seems to play a major role in the
decision to quit. Broader usage could therefore be reached
through lower out-of-pocket price and greater efficacy.
Secondary aspects such as side effects and weight gain
should also be taken into consideration. Coverage of such
treatments by the basic health insurance plan, or a subsidy
targeted at the most deprived smokers, whose average rates
of successful cessation are significantly lower than those of
the rest of the population, are some of the possible policy
options that are likely to lead to higher smoking cessation
rates.
Results also show that opting out is influenced by
several individual characteristics. Longer-term smokers
and individuals reporting frequent anxiety are more
likely to opt out, whereas individuals with higher edu-
cation and with children in the household are less likely
to opt out. Even current smokers who previously used a
smoking cessation support (i.e., unsuccessful quitters) are
less likely to opt out. This may indicate that they better
perceive the potential benefits of using such products or
simply that they have particular underlying characteris-
tics that influence their choice and that are not altered by
previous experience with the good. From a methodo-
logical point of view, we show the limitations of the
simple multinomial logit model and therefore the
importance of using more sophisticated models to study
data from a discrete choice experiment. The nested logit
models provide interesting insights in the opt-out deci-
sion and taking unobserved heterogeneity into account
using the random parameter logit approach significantly
improves the models.
However, this study has notable limitations. First, the
respondents did not stem from a random national sample,
and the sample is not very large (N = 131); their pref-
erences may therefore not be representative of those of
the general Swiss population of smokers. In addition, on
the basis of existing literature, it is not possible to rule
the validity of an analysis of preference heterogeneity
with this sample size. Second, the use of a stated
preference method raises the issue of hypothetical bias.
However, the method provides many insights about the
determinants of choice and allows for the capturing of
the effects of features that are simply not available on
the market or that do not vary enough in current alter-
natives. It could be useful to use real market data about
smoking cessation medication sales and merge them with
stated preference data resulting from a DCE. This would
combine the advantages of both methodologies, i.e., the
market equilibrium assessment (market data) with the
analysis of trade-offs between attributes (DCE data).
Third, we must keep in mind that, as explained in Kjaer
et al. [58], the fact that price is always placed as the first
attribute in the choice sets could have led to an over-
estimation of the WTP estimates.
It is important to keep in mind that we focus here
only on the preferences of potential consumers. A
number of other agents are involved in the smoking
cessation drug market, including pharmaceutical compa-
nies that have incentives to promote their products,
general practitioners that have a central influence in
delivering the right to purchase (at least for drugs that
are not sold OTC), and also public health authorities,
who play a role in increasing the perceived benefits of
smoking cessation and in deciding drug reimbursements.
According to the 2007/2008 Swiss Tobacco Survey
results, almost 80% of all smokers have already
discussed tobacco use with their general practitioner or
dentist. One in five smokers in Switzerland has been
proposed cessation support from their physician; a vast
majority of advice was focused on NRTs (35%) and
books (25%). Zyban and Champix were proposed only
8 and 5% of the time, respectively [59]. A potential
extension of this research would be to study physicians’
behaviour and incentives to prescribe such drugs and to
assess what part of the decision is induced by potential
quitters and what part is caused by the physician. The
implications of a possible reimbursement contingent on
successful cessation that could provide the best incentive
for people to engage in quitting behaviour should also be
analysed in the Swiss setting. Other extensions would be
to analyse preferences using a labelled DCE as Paterson
et al. [30] did, including Champix (varenicline) as an
additional alternative, and to apply Latent Class Models
to further investigate preference heterogeneity [60].
Appendix
See Table 9.
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